tetano
Editor, Senior Moderator
Commun Biol
. 2021 Jun 3;4(1):682.
doi: 10.1038/s42003-021-02220-z.
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
Jungang Chen[SUP] 1 [/SUP], Lu Dai[SUP] 1 [/SUP], Lindsey Barrett[SUP] 1 [/SUP], Jennifer James[SUP] 1 [/SUP], Karlie Plaisance-Bonstaff[SUP] 2 [/SUP], Steven R Post[SUP] 1 [/SUP], Zhiqiang Qin[SUP] 3 [/SUP]
Affiliations
Affiliations
Abstract
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected almost one hundred million people since the end of 2019, killed over two million, and caused worldwide social and economic disruption. Because the mechanisms of SARS-CoV-2 infection of host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy. Besides severe respiratory and systematic symptoms, several comorbidities increase risk of fatal disease outcome. Therefore, it is required to investigate the impacts of COVID-19 on pre-existing diseases of patients, such as cancer and other infectious diseases. In the current study, we report that SARS-CoV-2 encoded proteins and some currently used anti-COVID-19 drugs are able to induce lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV), one of major human oncogenic viruses, through manipulation of intracellular signaling pathways. Our data indicate that those KSHV + patients especially in endemic areas exposure to COVID-19 or undergoing the treatment may have increased risks to develop virus-associated cancers, even after they have fully recovered from COVID-19.
. 2021 Jun 3;4(1):682.
doi: 10.1038/s42003-021-02220-z.
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
Jungang Chen[SUP] 1 [/SUP], Lu Dai[SUP] 1 [/SUP], Lindsey Barrett[SUP] 1 [/SUP], Jennifer James[SUP] 1 [/SUP], Karlie Plaisance-Bonstaff[SUP] 2 [/SUP], Steven R Post[SUP] 1 [/SUP], Zhiqiang Qin[SUP] 3 [/SUP]
Affiliations
Affiliations
- [SUP]1[/SUP] Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- [SUP]2[/SUP] Department of Medicine, Louisiana State University Health Sciences Center, Louisiana Cancer Research Center, New Orleans, LA, USA.
- [SUP]3[/SUP] Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. zqin@uams.edu.
- PMID: 34083759
- DOI: 10.1038/s42003-021-02220-z
Abstract
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected almost one hundred million people since the end of 2019, killed over two million, and caused worldwide social and economic disruption. Because the mechanisms of SARS-CoV-2 infection of host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy. Besides severe respiratory and systematic symptoms, several comorbidities increase risk of fatal disease outcome. Therefore, it is required to investigate the impacts of COVID-19 on pre-existing diseases of patients, such as cancer and other infectious diseases. In the current study, we report that SARS-CoV-2 encoded proteins and some currently used anti-COVID-19 drugs are able to induce lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV), one of major human oncogenic viruses, through manipulation of intracellular signaling pathways. Our data indicate that those KSHV + patients especially in endemic areas exposure to COVID-19 or undergoing the treatment may have increased risks to develop virus-associated cancers, even after they have fully recovered from COVID-19.